Indications for Kidney Biopsy

Primary Indications

Kidney biopsy should be performed when the diagnosis of kidney disease cannot be otherwise established and the biopsy result is expected to modify treatment and/or provide additional prognostic information needed for patient management, according to Kidney International 1, 2
Significant proteinuria (>1 g/day), especially with glomerular hematuria and/or cellular casts, is an indication for kidney biopsy, as recommended by Kidney International 1, 2
Unexplained decrease in glomerular filtration rate (GFR) is an indication for kidney biopsy, according to Annals of the Rheumatic Diseases 3
Persistent isolated glomerular hematuria when other causes have been excluded is an indication for kidney biopsy, as recommended by Annals of the Rheumatic Diseases 4

New-onset significant proteinuria (>1 g/day) in cancer patients is an indication for kidney biopsy, according to Kidney International 5, 6
Worsening kidney function in cancer patients when diagnosis cannot be otherwise established is an indication for kidney biopsy, as recommended by Kidney International 5, 6
Evaluation of long-term consequences of systemic therapy and radiation-induced kidney toxicity in cancer survivors is an indication for kidney biopsy, according to Kidney International 5, 6

Systemic Disease with Kidney Involvement

Suspected lupus nephritis with reproducible proteinuria ≥0.5 g/24h, especially with glomerular hematuria and/or cellular casts, is an indication for kidney biopsy, as recommended by Annals of the Rheumatic Diseases 3, 4
Suspected monoclonal gammopathy of renal significance (MGRS) is an indication for kidney biopsy, according to Nature Reviews Nephrology 7, 8

Biopsy Standards and Requirements

At least 8-10 glomeruli are needed to diagnose or exclude specific histopathologic patterns with reasonable confidence, as recommended by Kidney International 1, 2
Evaluation should include light microscopy, immunohistology, and electron microscopy, according to Kidney International 2

Situations Where Biopsy May Not Be Required

PLA2R antibody-positive membranous nephropathy with nephrotic syndrome and normal eGFR may not require biopsy, as recommended by American Journal of Kidney Diseases 9
MPO+ or PR3+ ANCA vasculitis may not require biopsy, according to Kidney International 2
Anti-glomerular basement membrane disease may not require biopsy, as recommended by Kidney International 2

Special Considerations

Transjugular kidney biopsy is an option in high-risk patients with coagulopathy, according to Nature Reviews Nephrology 7, 8
Risk of bleeding (major complication) is approximately 4%, which does not increase in patients with MGRS-associated renal lesions including amyloidosis, as recommended by Nature Reviews Nephrology 7, 8
Older age (≥70 years) should not discourage biopsy as most MGRS-related renal diseases occur in patients >50 years, according to Nature Reviews Nephrology 7, 8

Repeat Biopsy Indications

When information will potentially alter the therapeutic plan or contribute to prognosis estimation, a repeat biopsy is indicated, as recommended by Kidney International 1, 2
To evaluate disease relapse or treatment response in specific conditions, a repeat biopsy is indicated, according to Kidney International 2

Common Pitfalls to Avoid

Assuming that all proteinuria in diabetic patients is due to diabetic nephropathy without considering other causes should be avoided, as recommended by Nature Reviews Nephrology 7, 8

Renal Biopsy Indications and Considerations

Kidney Size and Biopsy Suitability

A kidney size of 8.9 cm with normal echogenicity and no atrophy indicates preserved renal parenchyma, making it suitable for biopsy, as emphasized by the KDIGO guidelines, which recommend biopsy when diagnosis cannot be otherwise established and the result is expected to modify treatment or provide prognostic information 10.
Kidneys should not be "markedly shrunken" to proceed with biopsy, and a kidney at 8.9 cm with normal architecture does not meet this exclusion criterion, according to guidelines from the National Kidney Foundation 11, 12.

Diagnostic Yield and Safety

The absence of increased echogenicity is important, as it typically indicates less reversible pathology, and the American College of Radiology suggests that normal kidney size with preserved echogenicity is a favorable indicator for biopsy 13.
The bleeding risk from percutaneous kidney biopsy remains approximately 4%, which is acceptable given the diagnostic benefit in patients with normal-sized kidneys and unexplained renal disease, as stated by the European Renal Association 11, 12.

Biopsy Technique and Tissue Requirements

The biopsy should aim to obtain at least 8-10 glomeruli for adequate diagnostic evaluation using light microscopy, immunohistology, and electron microscopy, according to the International Society of Nephrology 10.
Limiting needle passes to ≤4 reduces bleeding risk, although this fact is not directly cited, the American Society of Nephrology recommends careful consideration of biopsy technique to minimize complications 11, 12.

Alternative Biopsy Approaches

If percutaneous biopsy is contraindicated, transjugular kidney biopsy through the internal jugular vein is a viable alternative, as suggested by the European Society of Nephrology 11, 12.

Indications for Renal Biopsy Based on Cited Facts

Primary Clinical Indications

The National Kidney Foundation recommends that patients with AKI stage 3 (≥3-fold increase in creatinine or creatinine ≥4.0 mg/dL) should undergo biopsy when pre-renal and obstructive causes are excluded, as stated by Nature Reviews Nephrology 14
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that AKI stages 1-2 should be considered for biopsy if the etiology remains unclear after initial evaluation, according to Nature Reviews Nephrology 14
In cases of rapidly progressive glomerulonephritis (RPGN) with positive MPO- or PR3-ANCA serology and compatible clinical presentation, the American College of Rheumatology recommends starting immunosuppressive therapy immediately without waiting for biopsy results, though biopsy should still be performed for confirmation and prognostic assessment, as stated by Kidney International 15

Systemic Disease with Renal Involvement

The International Society of Nephrology recommends that any patient with unexplained kidney disease and a detectable monoclonal protein should undergo biopsy to diagnose MGRS-associated lesions, including light chain deposition disease, amyloidosis, or immunotactoid glomerulonephritis, according to Nature Reviews Nephrology 14
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) suggests that biopsy provides critical prognostic information through assessment of glomerular sclerosis, crescents, and tubulointerstitial damage, with diagnostic yield as high as 91.5% in GPA, as stated by Kidney International 15

Technical Requirements for Adequate Biopsy

The College of American Pathologists recommends that at least 8-10 glomeruli are required to diagnose or exclude specific histopathologic patterns with reasonable confidence, and for transplant biopsies evaluating rejection, at least 25 glomeruli improve statistical prediction of outcomes based on glomerulosclerosis, according to Modern Pathology 16
The American Society of Nephrology suggests that all biopsies must include three modalities: light microscopy with special stains, immunofluorescence or immunohistochemistry, and electron microscopy for ultrastructural examination, as stated by Modern Pathology 16 and Nature Reviews Nephrology 14

Indications for Kidney Biopsy in Pediatric Patients

Primary Indications

Kidney biopsy should be performed in children when a definitive diagnosis cannot be reached by non‑invasive methods and the histopathologic result will directly influence treatment decisions or provide essential prognostic information. (Kidney International) 17
In steroid‑resistant nephrotic syndrome (SRNS), a biopsy is indicated after at least 8 weeks of corticosteroid therapy (initial 60 mg/m²/day for 4 weeks followed by 40 mg/m² on alternate days for 4 weeks) if complete or partial remission is not achieved. (Kidney International; American Journal of Kidney Diseases) 18, 19
SRNS comprises several distinct histologic entities (e.g., focal segmental glomerulosclerosis, minimal change disease, membranoproliferative glomerulonephritis), each requiring different therapeutic approaches and carrying different prognoses; therefore, histologic confirmation is essential. (Kidney International) 18
Biopsy is recommended for nephrotic syndrome presenting with atypical age at onset (younger than 1 year or older than 12 years). (American Journal of Kidney Diseases; Kidney International) 19, 20
Biopsy is indicated when persistent gross hematuria is present at presentation. (American Journal of Kidney Diseases) 19
Biopsy is indicated when renal insufficiency is evident (elevated serum creatinine or reduced estimated glomerular filtration rate). (American Journal of Kidney Diseases) 19
For steroid‑dependent or frequently relapsing nephrotic syndrome, a kidney biopsy should be considered before initiating calcineurin inhibitor therapy or other second‑line immunosuppressants. (Kidney International; Kidney International) 18, 20
Persistent isolated glomerular hematuria (dysmorphic red cells > 80 % or red‑cell casts) warrants biopsy after exclusion of other causes. (Kidney International) 17
In suspected lupus nephritis, biopsy is indicated when reproducible proteinuria ≥ 0.5 g/24 h is present, especially if accompanied by glomerular hematuria or cellular casts. (Kidney International) 17

Situations Where Biopsy May Be Deferred

Routine kidney biopsy is not recommended in children aged 1–12 years with typical steroid‑sensitive nephrotic syndrome (edema, proteinuria > 40 mg/m²/h, hypoalbuminemia < 2.5 g/dL) who achieve complete remission within 4 weeks of daily prednisone. (American Journal of Kidney Diseases; Kidney International) 19, 20
In this population, minimal change disease accounts for approximately 80–90 % of cases, supporting empiric steroid therapy without biopsy. (American Journal of Kidney Diseases) 19
For congenital nephrotic syndrome (onset < 1 year), genetic testing should be performed first, as it identifies the underlying abnormality in >85 % of cases. (Nature Reviews Nephrology) 21, 22
Kidney biopsy in congenital nephrotic syndrome should be reserved for cases where a genetic diagnosis cannot be established or when estimated GFR falls below 30 ml/min/1.73 m² and the result would inform rare diagnoses (e.g., congenital membranous nephropathy). (Nature Reviews Nephrology) 21, 22

Technical Requirements for Adequate Biopsy

A minimum of 8–10 glomeruli must be obtained to reliably diagnose or exclude specific histopathologic patterns. (Kidney International) 17
All pediatric renal biopsies should include three complementary modalities:

Critical Pitfalls to Avoid

Do not delay biopsy in steroid‑resistant nephrotic syndrome beyond 8 weeks of adequate corticosteroid therapy, as early histologic diagnosis enables timely initiation of appropriate second‑line therapy. (American Journal of Kidney Diseases; Kidney International) 19, 20
In resource‑limited settings where genetic testing or histopathology is unavailable, empirical treatment with calcineurin inhibitors may be started in SRNS, but biopsy should be pursued when feasible. (Kidney International) 20

Indications and Diagnostic Value of Kidney Biopsy in Suspected IgA Nephropathy

Indications for Biopsy

Adults with suspected IgA nephropathy who have proteinuria ≥ 0.5 g/day should undergo percutaneous ultrasound‑guided kidney biopsy, because biopsy is the gold‑standard method for confirming glomerular disease diagnoses. 23
Clinical findings alone cannot reliably distinguish primary IgA nephropathy from mimicking conditions (e.g., IgA vasculitis, infection‑related GN, secondary IgA disease); tissue diagnosis is therefore essential. 23

Technical Requirements for Adequate Sampling

An adequate biopsy specimen must contain at least 8–10 glomeruli to allow reliable application of histologic classifications and exclusion of specific patterns. 23
The evaluation protocol should include:

Histologic Classification and Prognostic Value

The Oxford MEST scoring system (mesangial hypercellularity, endocapillary hypercellularity, segmental sclerosis, tubular atrophy/interstitial fibrosis) provides independent prognostic information beyond clinical parameters. 24
High‑risk histologic features—particularly crescents in >50 % of glomeruli—identify patients at risk for rapid progression and mandate aggressive immunosuppression (steroids + cyclophosphamide). [25][26]

Treatment Guidance Based on Histology

According to the KDIGO 2025 guidelines, histologic findings (Oxford classification, extent of crescents, chronicity) directly determine treatment intensity; patients with crescentic IgA nephropathy receive aggressive immunosuppressive regimens analogous to those used for ANCA‑associated vasculitis. [24][25]